Table 3 PCV13 and PPSV23 effectiveness to prevent IPD in inpatient and outpatient pneumonia in adults over 50 years not previously vaccinated in the first year after vaccination
From: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
| Age groups (years) | PCV13 | PPSV23 | ||||
|---|---|---|---|---|---|---|
| IPD [14],[33],[34] | Inpatient pneumonia [28] | Outpatient pneumonia [10] | IPD [26],[27],[31],[32] | Inpatient pneumonia [37]-[42] | Outpatient pneumonia [37]-[42] | |
| 50 – 64 | 88.9% | 24.2% | 5.6% | 79.2% | 0.0% | 0.0% |
| 65 – 74 | 81.5% | 21.9% | 5.1% | 61.6% | 0.0% | 0.0% |
| 75 – 79 | 75.7% | 20.2% | 4.7% | 50.4% | 0.0% | 0.0% |
| 80 – 99 | 70.3% | 18.7% | 4.3% | 42.1% | 0.0% | 0.0% |
